Get the Stockscreener App
2.305
0.65%
-0.015
After Hours:
2.33
0.025
+1.08%
Atai Life Sciences N V stock is traded at $2.305, with a volume of 1.34M.
It is down -0.65% in the last 24 hours and up +53.67% over the past month.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
See More
Previous Close:
$2.32
Open:
$2.26
24h Volume:
1.34M
Relative Volume:
0.74
Market Cap:
$461.78M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-8.2321
EPS:
-0.28
Net Cash Flow:
$-84.71M
1W Performance:
+11.89%
1M Performance:
+53.67%
6M Performance:
+29.49%
1Y Performance:
+37.20%
1-Day Range:
$2.18
$2.3299
1-Week Range:
$2.0801
$2.3799
52-Week Range:
$1.03
$2.565
Atai Life Sciences N V Stock (ATAI) Company Profile
Name
Atai Life Sciences N V
Sector
Industry
Phone
49 89 2153 9035
Address
WALLSTRASSE 16, BERLIN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
2.305 | 404.68M | 314.00K | -40.23M | -84.71M | -0.28 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Life Sciences N V Stock (ATAI) Latest News
atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know - Nasdaq
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance
atai Life Sciences holds annual general meeting - Investing.com Australia
atai Life Sciences holds annual general meeting By Investing.com - Investing.com India
ATAI Life Sciences Approves Key Governance Changes - TipRanks
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies - Yahoo Finance
ATAI Life Sciences Sees Significant Rise in Borrow Rate | ATAI S - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL-003 | ATAI Stock News - GuruFocus
ATAI Life Sciences (ATAI) Shows Encouraging Mid-Stage Trial Resu - GuruFocus
atai Life Sciences reports positive data from mid-stage depression trial - Seeking Alpha
ATAI Reiterates a 'Buy' Rating with a Price Target of $10 | ATAI Stock News - GuruFocus
Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug - marketscreener.com
ATAI Life Sciences Reports Promising Findings from Depression Study | ATAI Stock News - GuruFocus
atai reports positive phase 2a results for depression treatment By Investing.com - Investing.com UK
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - Yahoo Finance
How Do Things Look For ATAI Life Sciences N.V (NASDAQ: ATAI) In The Short-Term? - Stocksregister
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt - simplywall.st
ATAI Explores Psychedelic Solutions for Veterans' Mental Health - GuruFocus
ATAI Explores Psychedelic Solutions for Veterans' Mental Health | ATAI Stock News - GuruFocus
ATAI Reports Narrower Q1 Loss and Initiates Key Clinical Study | ATAI Stock News - GuruFocus
Atai Life Sciences: Progress in Psychedelic Mental Health Treatments - TipRanks
Will Atai Get A New Lease Of Life? - RTTNews
Atai Life Sciences Reports First Quarter 2025 Financial Results - marketscreener.com
ATAI Reports Significant First Quarter Revenue Growth | ATAI Sto - GuruFocus
ATAI Sees Financial Boost with Cash Reserves Rise | ATAI Stock N - GuruFocus
ATAI Reports Significant First Quarter Revenue Growth | ATAI Stock News - GuruFocus
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - The Manila Times
Certain Restricted stock units of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Options of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
ATAI Begins Phase 2 Study for Social Anxiety Treatment | ATAI St - GuruFocus
Atai Life Sciences Announces First Patient Dosed In Phase 2 Study Of Emp-01 For The Treatment Of Social Anxiety Disorder - marketscreener.com
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - Yahoo
ATAI Life Sciences Repays Hercules Loan Early - TipRanks
Daily Market Movement: ATAI Life Sciences N.V (ATAI) Sees a -2.00 Decrease, Closing at 1.47 - DWinneX
ATAI Life Sciences N.V [ATAI] Records 50-Day SMA of $1.4948 - knoxdaily.com
ATAI Life Sciences N.V: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Have you been able to find a good deal on ATAI Life Sciences N.V’s shares? - uspostnews.com
Atai Life Sciences N.V. Announces Executive Changes - marketscreener.com
ATAI Life Sciences N.V (ATAI)’s Market Momentum: Closing Strong at 1.51, Down -3.82 - DWinneX
An Analysis of ATAI Life Sciences N.V (ATAI)’s Potential Price Growth - knoxdaily.com
ATAI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
ATAI Life Sciences N.V [ATAI] stock for 65,560 USD was sold by Kirpekar Sahil - knoxdaily.com
How Will ATAI Life Sciences N.V (NASDAQ: ATAI) Perform In Months To Come? - Marketing Sentinel
Investing in ATAI Life Sciences N.V (ATAI) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating - Seeking Alpha
Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine
At What Point In Time Would I Choose To Purchase ATAI Life Sciences N.V (NASDAQ: ATAI) Stock? - stocksregister.com
Atai Life Sciences N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atai Life Sciences N V Stock (ATAI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Craig Kevin James | Chief Medical Officer |
Mar 21 '25 |
Sale |
1.35 |
11,563 |
15,610 |
8,437 |
| Rao Srinivas | See Remarks |
Mar 21 '25 |
Sale |
1.35 |
75,418 |
101,814 |
212,942 |
| Johnson Anne Nagengast | Chief Financial Officer |
Mar 21 '25 |
Sale |
1.35 |
33,545 |
45,286 |
140,045 |
| Short Glenn Frank | Chief Scientific Officer |
Mar 21 '25 |
Sale |
1.35 |
13,161 |
17,767 |
42,333 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):